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Abstract
Background: Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a bleeding disorder caused by maternal
antibodies against paternal human platelet antigens (HPAs) on fetal platelets. Antibodies against HPA-1a are
accountable for the majority of FNAIT cases. We have previously shown that high levels of maternal anti-HPA-1a
antibodies are associated with clinically significant reduced birth weight in newborn boys. Chronic inflammatory
placental lesions are associated with increased risk of reduced birth weight and have previously been reported in
connection with FNAIT pregnancies. The HPA-1a epitope is located on integrin β3 that is associated with integrin
αIIb (the fibrinogen receptor) on platelets and megakaryocytes. Integrin β3 is also associated with integrin αV
forming the αVβ3 integrin heterodimer, the vitronectin receptor, which is expressed on various cell types, including
trophoblast cells. It is therefore thinkable that maternal anti-HPA-1a antibodies present during early pregnancy may
affect placenta function through binding to the HPA-1a antigen epitope on invasive throphoblasts. The aim of the
study was to examine whether interaction of a human anti-HPA-1a monoclonal antibody (mAb) with HPA-1a on
trophoblast cells affect adhesion, migration and invasion of extravillous trophoblast cells.
Methods: An in vitro model with human anti-HPA-1a mAb, clone 26.4, and the first trimester extravillous trophoblast
cell line HTR8/SVneo was employed. The xCELLigence system was utilized to assess the possible effect of anti-HPA-1a
mAb on adhesion and migration of HTR8/SVneo cells. Specially designed chambers precoated with Matrigel were used
to assess the effect on the invasive capacity of cells.
Results: We found that human anti-HPA-1a mAb 26.4 partially inhibits adhesion and migratory capacity of
HTR8/SVneo cells.
Conclusions: Our findings suggest that anti-HPA-1a antibodies may affect trophoblast functions crucial for
normal placental development. Future studies including primary throphoblast cells and polyclonal anti-HPA-1a
antibodies are needed to confirm these results.
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Background
Fetal and neonatal alloimmune thrombocytopenia (FNAIT)
is caused by maternal antibodies against alloantigens
on fetal platelets. It is a rare, but potentially life threat-
ening disorder with intracranial hemorrhage (ICH) as
the most severe complication. Severe gastrointestinal
and pulmonary hemorrhages have also been reported [1].
Antibodies against human platelet antigen (HPA)-1a
are accountable for nearly 85% of FNAIT cases [2]. The
frequency of FNAIT due to anti-HPA-1a antibodies is
around one per 1100 live births [2, 3]. We have previ-
ously found that high levels of maternal anti-HPA-1a
antibodies are associated with clinically significant re-
duced birth weight in newborn boys [4]. A similar ob-
servation was made in an international multicenter
study of FNAIT-associated ICH, showing that 23% of
neonates with ICH were small for gestational age [5].
Chronic inflammatory placental lesions like chronic vil-
litis and intervillositis have been reported in association
with FNAIT cases [6] and such placental lesions are
known to be associated with increased risk of fetal
growth restriction.
Integrin β3, carrying the HPA-1 antigen epitope, is
expressed on platelets and megakaryocytes as part of
αIIbβ3 integrin heterodimer, the fibrinogen receptor.
Integrin β3 is also associated with αV integrin forming
integrin heterodimer αVβ3, also known as vitronectin
receptor. The vitronectin receptor is expressed on vari-
ous cell types, including trophoblast cells [7–9].
During early pregnancy, a population of trophoblast
cells differentiates into highly invasive extravillous tro-
phoblasts (EVT). EVT invade the decidualized endomet-
rium reaching the inner third of the myometrium, and
migrate along the spiral arteries remodeling them into
large diameter low resistance vessels [10]. EVT migration
and invasion into the uterus continues until mid-gestation
and is regulated by various factors of both maternal and
embryonic origin [11]. Impaired trophoblast invasion and
insufficient remodeling of placental spiral arteries are
common histopathological findings in placentas from
pregnancies complicated by preeclampsia and low birth
weight [12, 13].
During migration and invasion, EVT cells undergo in-
tegrin switch and upregulate expression of adhesion
molecules on cell surface, including the αVβ3 [8, 14].
The important role of αVβ3 in mediating migration and
invasion of primary cytotrophoblasts (CTB) was demon-
strated in vitro [8, 15]. It has therefore been speculated
that anti-HPA-1a antibodies may affect placental devel-
opment [4]. Anti-HPA-1a antibodies can bind HPA-1a
on αVβ3 expressed on trophoblast cells [9, 16], and we
hypothesize that this binding may affect EVT invasion,
spiral artery remodeling, and in turn lead to reduced
placental function.
The objective of this study was to test whether anti-
HPA-1a antibodies affect adhesion, migration and inva-
sive capacity of EVT cells. For functional experiments
we used an experimental in vitro model with human re-
combinant anti-HPA-1a monoclonal antibody (mAb),
clone 26.4 [16], and a first trimester human EVT-derived
cell line, HTR8/SVneo [17].
Methods
Cell culture
Human first trimester extravillous trophoblast-derived
cell line, HTR8/SVneo, was kindly provided by Charles
Graham (Department of Anatomy and Cell Biology at
Queen’s University, Kingston, ON, Canada). The cell line
was generated by immortalization of primary villous
explant culture from first trimester human placenta
(8–10 WG) with SV40 virus [17]. HTR8/SVneo is a
hypotriploid cell line (3n-) [18]. Cells were cultured in
RPMI-1640 (Sigma-Aldrich, St. Louis, MO), supple-
mented with 10% FBS (Lonza, Basel, Switzerland), 100
U/ml penicillin, 100 U/ml streptomycin (Lonza) and
maintained at 37 °C, in a 5% CO2 humidified atmos-
phere. The cells were grown to 70–80% confluency
and passaged 24 h prior to experiments. The cells
were detached by incubation with 2 mM EDTA in PBS
for 5 min at 37 °C.
Antibodies
A recently developed human recombinant anti-HPA-1a
IgG1 mAb (clone 26.4) [16] was used to explore the ef-
fect on invasive trophoblast cells. Murine anti-human
αVβ3 mAb, clone LM609 (Millipore, Billerica, MA) was
used as positive control for cell functional studies. So-
dium azide from LM609 sample was removed by buffer
exchange with PBS using PD SpinTrap G-25 (GE
Healthcare, Little Chalfont, UK). Integrin β3 was detected
using murine mAb, clone SZ21, HPA-1-reactive [19] (Dako,
Glostrup, Denmark) and rabbit mAb, clone EPR2417Y
(Abcam, Cambridge, UK). Alexa Fluor 488-conjugated goat
anti-mouse and goat anti-human antibodies (Invitrogen,
Carlsbad, CA) were used as secondary antibodies in flow
cytometry experiments. Human myeloma plasma IgG1
(Sigma) and murine IgG1 (Beckman Coulter, Brea, CA)
were used as isotype controls. Horseradish peroxidase
(HRP)-conjugated goat anti-rabbit IgG (Thermo Scientific,
Waltham, MA) was used as a detection antibody in the
western blot experiment.
Western blot
Platelets from an HPA-1aa-genotyped donor (16 × 108
cells) and HTR8/SVneo cells (20 × 106 cells) were lysed
using 3 ml RIPA buffer (Sigma) in the presence of prote-
ase inhibitor (cOmplete Tablets Mini EDTA-free, Roche
Diagnostics, Basel, Switzerland). Twelve microliters of
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platelet lysate diluted 1:1000 and 12 μl of HTR8/SVneo
cell lysate were reduced and separated in a 4–12% SDS
polyacrylamide gel (Life Technologies, Carlsbad, CA).
Electrophoresed samples were transferred to a PVDF
membrane (Life Technologies). Nonspecific binding sites
were blocked by Super blocking buffer (Thermo Scien-
tific) containing 0.05% Tween 20 and 0.2% goat IgG
(Thermo Scientific) for 1 h. Primary and secondary anti-
bodies were diluted in Super blocking buffer containing
0,05% Tween 20. The PVDF membrane was incubated
overnight at 4 °C with rabbit anti-β3 antibody diluted
1:2000 (clone EPR2417Y). After a washing step, the
membrane was incubated with HRP-conjugated goat
anti-rabbit IgG diluted 1:1000 for 1 h at RT followed by
a washing step with PBS 0.05% Tween 20. The mem-
brane was covered by 3 ml of Supersignal West Femto
Maximum Sensitivity Substrate (Thermo Scientific) and
left for 5 min in the dark at RT. Integrin β3 was visualized
using the luminescent image analyzer ImageQuant LAS
4000 (GE Healthcare, Little Chalfont, UK). Integrin αVβ3
purified from human placenta was used as a positive con-
trol (Millipore, Billerica, MA). The expected β3 subunit
band is of approximately 90–110 kDa.
Flow cytometry
To stain cell surface membrane integrins, the HTR8/
SVneo cells were harvested, washed and re-suspended in
PBS 0.2% bovine serum albumin, and incubated 10 min
at RT with unconjugated mouse anti-human β3 (clone
SZ21) or human anti-HPA-1a (clone 26.4) mAbs. Mouse
and human IgG1 were used as isotype controls. After
a washing step, cells were stained with Alexa Fluor
488-conjugated goat anti-mouse and goat anti-human
antibodies respectively, and analyzed by flow cytometry
(Canto, Becton Dickinson, Franklin Lakes, NJ). The ac-
quired data was analyzed using FlowJo software (TreeStar,
Ashland, OR, USA).
HPA-1 genotyping
The DNA and RNA from HTR8/SVneo cells and donor
samples were isolated and used for HPA-1 genotyping
by TaqMan 5′ nuclease assay as described previously
[20, 21].
Y-chromosome DNA test
The DNA isolated from HTR8/SVneo cells was used for
Y-chromosome DNA test by TaqMan 5′ nuclease assay.
The primers used for the assay were described previ-
ously [22] and FAM-labelled probe was designed in
house.
Monitoring cell adhesion and migration
Cell adhesion and migration were monitored in real time
using the xCELLigence system (Roche Applied Science,
Penzberg, Germany) [23]. For determining the rate of
cell adherence, E-plate 16 assemblies were coated with
human vitronectin (Promega, Madison, WI) by incubat-
ing 1 μg/ml solution in 100 μl volume for 1 h at 37 °C.
The wells were washed twice with PBS before 50 μl
complete medium was added and the background mea-
surements recorded. The cells were seeded at 20,000
cells/well in a 40 μl volume. From a solution of 200 μg
antibodies/ml PBS, 10 μl were added to each well (hu-
man IgG1 as negative control, 26.4 and LM609). Each
plate was then assembled on the RTCA DP analyzer, and
data were gathered at 5-min intervals for 7 h at 37 °C, in
a 5% CO2 humidified atmosphere.
Cell migration was monitored using specially designed
CIM-plate 16 with 8-μm pores. The sensor side (bottom
side) of each well of the upper chamber was coated with
human vitronectin by incubating 30 μl of the 1 μg/ml
solution for 30 min at RT. The lower chambers were
filled with medium containing 10% FBS, used as chemo-
attractant. The upper chambers were filled with serum-
free medium (50 μl/well), and the plate was incubated at
37 °C in 5% CO2 for 1 h. After recording background
measurements, the cells were seeded into the upper
chamber at 40,000 cells in 40 μl per well and 10 μl of
200 μg/ml antibodies in PBS were added. The plate was
then incubated for 30 min at RT, assembled on the
RTCA DP analyzer and data collected every 15 min for
24 h at 37 °C, in a 5% CO2 humidified atmosphere. The
obtained data were analyzed using the RTCA 1.2 soft-
ware supplied with the instrument.
Invasion assay
Cell invasion was evaluated using BD BioCoat Matrigel
Invasion Chambers (BD Biosciences). The Chambers (24
well Plate 8 Micron with Control inserts) were prepared
following the manufacturer’s instructions. The RPMI
1640 medium with 5% FBS was used as chemoattractant.
HTR8/SVneo cells were seeded into each insert at
40,000 cells/well in a 180 μl volume in serum free
medium and 20 μl of 200 μg/ml antibodies in PBS were
added (total antibody concentration of 20 μg/ml). The
plate was incubated for 48 h at 37 °C, in a 5% CO2 hu-
midified atmosphere. After incubation, the non-invading
cells were scrubbed from the upper part of the inserts by
a cotton swab.
The invaded cells were measured by the MTT (3-[4,5-
dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide)
assay. The MTT (Sigma) at 5 mg/ml in RPMI 1640
medium without phenol red, was diluted 1:10 and 350 μl
of the dilution was added to each clean well. The inserts
were transferred to MTT solution and incubated for 2 h
at 37 °C, in a 5% CO2 humidified atmosphere. Next, the
inserts were transferred into clean wells with 220 μl of
0.04 M HCl in pure isopropanol and incubated for 5 min
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at RT. The inserts were removed and the solution trans-
ferred to centrifuge tubes and centrifuged for 2 min at
16,000 x g. Of the solution, 100 μl was transferred into a
96-well microtiter plate and absorption at 560 nm was
measured by an ELISA- reader (Multiskan Ex, Thermo
Scientific).
Statistical Analysis
A one-way analysis of variance (ANOVA) in SPSS soft-
ware (SPSS Inc., Chicago, IL, USA) was used to analyze
adhesion, migration and invasion experimental data. A
P-value of < 0.05 was considered significant. Sigma Plot
13 software (San Jose, CA) was used to present the data.
Results
A human anti-HPA-1a mAb 26.4 binds HPA-1a epitope on
HTR8/SVneo cells
Integrin β3 expression by HTR8/SVneo cells was
assessed with Western blot and flow cytometry tech-
niques. Both techniques demonstrated expression of integ-
rin β3 by HTR8/SVneo cells (Fig. 1a and b). The cells
expressed αV, but were negative for αIIb (data not shown),
indicating that HTR8/SVneo cells express β3 integrin only
in association with αV integrin. Next, HTR8/SVneo cells
were genotyped HPA-1ab. Finally, flow cytometry analysis
demonstrated that human anti-HPA-1a mAb bound to in-
tact HTR8/SVneo cells (Fig. 1a).
A human anti-HPA-1a mAb 26.4 partially inhibits adhesion
and migratory capacity of HTR8/SVneo cells
The effect of a mAb 26.4 on trophoblast cell adhesion
and migration was explored using the xCELLigence sys-
tem. mAb 26.4 was used at a concentration of 20 μg/ml,
which corresponds to about 400 IU/ml of anti-HPA-1a
antibody activity as measured by quantitative mAb
immobilization of platelet antigens (MAIPA) assay [24].
mAb 26.4 significantly inhibited adhesion and migration
of HTR8/SVneo cells to vitronectin-coated membranes
by 15–20% (Fig. 2a and b) and 18–23% (Fig. 2c and d),
respectively. Anti-αVβ3 murine mAb (clone LM609)
similarly inhibited adhesion and migration of HTR8/
SVneo cells (data not shown).
The effect of mAb 26.4 on invasive capacity of first tri-
mester trophoblast cells was studied utilizing Matrigel
pre-coated invasion chambers. The mAb inhibited inva-
sive capacity of cells in three out of four independent ex-
periments by 9, 15 and 25% (Fig. 3). The inhibition was
not statistically significant (p = 0.13). Anti-αVβ3 murine
mAb (clone LM609) did not affect invasive capacity of
HTR8/SVneo cells (data not shown).
HTR8/SVneo cells originate from a female conceptus
To identify whether HTR8/SVneo cells originate from a
female or male conceptus, the Y-chromosome DNA test
has been performed. HTR8/SVneo cells were tested
negative for Y-chromosome DNA, indicating that the
cells originate from a female conceptus.
Discussion
In the present study, we have demonstrated that a human
HPA-1a-specific mAb inhibit adhesion and migratory cap-
acity of EVT cells in an in vitro model.
To study the possible effect of anti-HPA-1a antibodies
on EVT we utilized transformed first trimester EVT-
derived cells (HTR8/SVneo cell line), which were re-
ported to share phenotypic and functional characteristics
of EVT cells [17, 25]. We have shown that HTR8/SVneo
cells express HPA-1a epitope as part of αVβ3 integrin
complex, and importantly, that anti-HPA-1a antibodies
interact with HPA-1a on these cells. In this study, we
used a human anti-HPA-1a mAb, clone26.4, generated
from a B cell derived from a woman HPA-1a immunized
in connection with pregnancy, who had two children af-
fected by FNAIT. mAb 26.4 was expressed recombi-
nantly and found to be highly specific for HPA-1a,
bound strongly to HPA-1a epitopes on αIIbβ3 from
platelets as well as αVβ3 from trophoblasts [16]. Thus,
the HTR8/SVneo cell line with mAb 26.4 could be a


























Fig. 1 Expression of integrin β3 and HPA-1a on HTR8/SVneo cells.
a Flow cytometric analysis of cells incubated with murine anti-human
β3 HPA-1-reactive mAb SZ21 and human HPA-1a-specific mAb 26.4, or
isotype control. b Detection of integrin β3 in lysed HTR8/SVneo cells
by Western blot. Integrin αVβ3 isolated from human placenta used as
control. Integrin β3 detected as a band of about 100 kDa in the control
and cell lysate. Western blot image was spliced to rearrange the order
of samples within one experiment. Dashed lines indicate where the
images were joined. Figure A and B are representative for at least
three independent experiments
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useful model to study possible effect of anti-HPA-1a
antibodies on EVT.
The idea that alloantibodies reactive with fetal integ-
rins expressed on trophoblast cells can impair placental
function is not new. A histological study of placentas
from FNAIT-affected pregnancies described chronic vil-
litis in pregnancies not treated with IVIG [26]. And in a
recent histopatological study, FNAIT was associated
with chronic chorioamnionitis, basal chronic villitis and
intervillositis [6]. In addition, a case of FNAIT associated
with massive chronic intervillositis has also been de-
scribed [27]. Chronic villitis and intervillositis are pla-
cental lesions known to be associated with poor fetal
growth [28, 29]. Further, an association between FNAIT
due to anti-HPA-1a antibodies and increased risk of
miscarriage has also been suggested, indicating that
placental development may be affected in early stages
of pregnancy [30, 31].
Vitronectin receptor, carrying HPA-1 antigen epitope,
is crucial for cell-matrix and cell-cell interactions, modu-
lating growth, survival, motility and differentiation of an-
giogenic endothelial cells (EC), osteoclasts, tumor cells
and other cell types [32]. Blocking αVβ3 was shown to


































































Fig. 2 Effect of anti-HPA-1a antibodies on EVT adhesion and migration. HTR8/SVneo cells were plated on E-plate 16 (for adhesion experiments)
and CIM-plate 16 (for migration experiments) in the presence of mAb 26.4 or human IgG1 as a negative control. Cell adhesion was monitored
using xCELLigence system over 7 h, and cell migration over 24 h. The samples were run in triplicates and experiments repeated three times each.
Each column represent the range in cell index of one sample run in triplicate. Results presented in the graphs (distinguished by experiment due
to high variations in cell index between the experiments) are from three independent experiments: a adhesion; c migration. Plots visualize cell



















Fig. 3 Effect of anti-HPA-1a antibodies on invasive capacity of EVT.
HTR8/SVneo cells were cultured in Matrigel coated chambers in the
presence of mAb 26.4 or human IgG1 as a negative control for 48 h.
The samples were run in quadruplicates and experiment repeated
four times. Each column represent the range in cell index of one
sample run in quadruplicate. Cell invasion was evaluated by
MTT-assay. The invasion data is expressed as the ratio of invasion
through the Matrigel Matrix and membrane relative to the migration
through the control membrane
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EC, and suppress angiogenesis [33–35] impede tumor
progression [36], and hinder osteoclast adhesion and mi-
gration [32]. The important role of αVβ3 in mediating
EVT cells invasion [8] and adhesion to ECs [37, 38] was
shown in vitro.
Further, the capacity of anti-HPA-1a antibodies to
affect αVβ3-expressing EC in vitro has been reported
[35, 39, 40]. Anti-HPA-1a maternal sera affected spread-
ing and monolayer integrity of human umbilical cord
endothelial cells (HUVEC) [39] and inhibited HUVEC
proliferation and formation of capillary-like networks
[35]. The latter findings suggest that anti-HPA-1a anti-
bodies can cause systemic vascular damage, impair
angiogenesis, and subsequently can be an independent
cause of FNAIT-associated ICH. Further, in a recent
study, Santoso S. with co-workers have shown that only
anti-HPA-1a antibodies binding selectively to the αVβ3
complex interfere with angiogenesis [40].
Mechanisms of inhibitory effects of anti-HPA-1a anti-
bodies are still incompletely understood. It has been
shown that anti-HPA-1a antibodies can impair angiogenic
and increase proapoptotic signaling in HUVECs [35]. It
has also been hypothesized that anti-HPA-1a IgG anti-
bodies block the ligand RGD binding site on αVβ3 and
αIIbβ3 by indirect competition (i.e., steric hindrance) [41].
The HPA-1a epitope is formed by only one amino acid
change, L33P, in integrin β3, and, therefore, all anti-
HPA-1a antibody epitopes overlap reacting with the L33
residue. Yet, anti-HPA-1a antibodies are reported to be
heterogeneous in their footprint on integrin β3 [42] and
binding affinity [43–45]. In fact, recently it was found
that antibodies of this specificity can be even more com-
plex; αVβ3-, αIIbβ3-specific, or bind antigen independently
of the complex [40]. Thus, the effect of a single mAb spe-
cific for HPA-1a, as used in this study, may not be repre-
sentative for different polyclonal antibody profiles among
immunized women. Still, our finding that an anti-HPA-1a
mAb could affect functions of HTR8/SVneo cells is inter-
esting, indicating that anti-HPA-1a antibodies may affect
functions of extravillous trophoblast cells in vivo.
Only male neonates had significantly reduced birth
weight in pregnancies with high levels of maternal anti-
HPA-1a antibodies in a retrospective observational study
[4]. Male sex of the fetus is a well known risk factor for
adverse pregnancy outcome [46]. Evidence is emerging
on the influence of fetal sex on placental development
and function [47]. The placenta displays sexually dis-
morphic differences in gene expression and responds to
maternal factors in a sex-dependent manner [48]. The
magnitude of the effects of anti-HPA-1a antibodies on
trophoblast cells may depend on the sex of the placenta.
In this study we used a cell line HTR8/SVneo which we
found to originate from a female placenta. In the follow
up studies, it is therefore important to compare the
effects of anti-HPA-1a antibodies on trophoblast cells
originating from male and female placentas.
Conclusions
We have demonstrated that a human anti-HPA-1a mAb
impaired adhesion and migratory capacity of EVT-
derived cell line in vitro. We speculate that anti-HPA-1a
antibodies may hinder placental development, and con-
sequently, may be involved in early pregnancy loss as
well as poor placental function. Further studies with pri-
mary trophoblast cells and maternal anti-HPA-1a sera,
together with a histopathological study of placentas from
pregnancies affected by FNAIT are important to support
our finding.
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